Skip to main content

Advertisement

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Article metrics

  • 892 Accesses

The original article was published in Journal of Hematology & Oncology 2017 10:153

Correction

The original article [1] contains two errors in Table 2:

  1. 1)

    The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.

  2. 2)

    The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.

Table 2 Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.

Reference

  1. 1.

    Liu X, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153.

Download references

Author information

Correspondence to Pagona Lagiou or Jin Li.

Additional information

The original article can be found online at https://doi.org/10.1186/s13045-017-0521-0.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Qin, S., Wang, Z. et al. Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 11, 5 (2018) doi:10.1186/s13045-017-0545-5

Download citation